COMPARATIVE ANALYSIS OF DIFFERENT FORMULATIONS FOR ENHANCING ORAL BIOAVAILABILITY OF POORLY WATER-SOLUBLE DRUGS
Main Article Content
Keywords
Formulations , Enhancing ,Oral Bioavailability , Poorly Water-Soluble Drugs
Abstract
A major obstacle in the development of new drugs is poor water solubility, which reduces the oral bioavailability of many therapeutic compounds. This study compares different formulation techniques used to increase the oral bioavailability of poorly water-soluble medications. We investigate the mechanisms of action of various formulations, such as lipid-based formulations, solid dispersions, cyclodextrins, and micronization. The efficacy of each strategy in enhancing medication absorption, solubility, and, ultimately, bioavailability is assessed. it formulation strategy's benefits and drawbacks are examined, with an emphasis on how well-suited it is for certain drug classes and physicochemical characteristics. Current study compare various methods in an effort to determine which ones are most likely to overcome solubility constraints and maximize medication delivery for medicines that are not highly soluble in water. This comparative study might be useful in advancing the creation of drugs that are more widely available and effective.
Downloads
References
• Byrne, M. E. (2008). Solid Dosage Forms and Drug Delivery Systems (2nd ed.). Taylor & Francis. (Chapter 2: Routes of Drug Administration) • Hirayama, N., & Uekama, K. (2009). Preparation and evaluation of novel DDS for poorly water-soluble drugs: cyclodextrin-based delivery systems. International Journal of Pharmaceutics, 372(1-2), 46-64. doi: 10.1016/j.ijpharm.2009.01.022: doi: 10.1016/j.ijpharm.2009.01.022 • Kalepu, S., Manthina, M., and Padavala, V. (2013a). Oral lipid-based drug delivery systems–an overview. Acta Pharm. Sin. B 3, 361–372. doi:10.1016/j.apsb.2013.10.001 • Lennox, R. (2017). Formulation strategies for poorly water-soluble drugs. Expert Opinion on Drug Delivery, 14(4), 403-416. doi: 10.1080/17425247.2017.1280373: doi: 10.1080/17425247.2017.1280373 • Pouton, C. W., and Porter, C. J. H. (2008). Formulation of lipid-based delivery • systems for oral administration: materials, methods and strategies. Adv. drug Deliv. Rev.60, 625–637. doi:10.1016/j.addr.2007.10.010 • Mancini, G., Gonçalves, L. M. D.,Marto, J., Carvalho, F. A., Simões, S., Ribeiro, H.M.,et al. (2021). Increased therapeutic efficacy of SLN containing etofenamate and ibuprofen in topical treatment of inflammation. Pharmaceutics 13, 328. doi:10.3390/pharmaceutics13030328 • Gunstone, F. D., and Harwood, J. L. (2007). “Occurrence and characterisation of oils and fats,” in The lipid handbook with CD-ROM (Boca Raton, FL: CRC Press), 51–156. • Santra, S., and Majee, S. B. (2022). Lipid based vehicles and lipid-based excipients in drug delivery. Res. J. Pharm. Technol. 15, 2334–2338. doi:10.52711/0974-360x.2022.00388 • Shargel, L., & Wu-Pong, S. (2005). Concepts in Dosage Form Design and Development (5th ed.). McGraw-Hill. (Chapter 1: Introduction) • Maji, I., Mahajan, S., Sriram, A., Medtiya, P., Vasave, R., Khatri, D. K., et al. (2021). • Solid self emulsifying drug delivery system: superior mode for oral delivery of • hydrophobic cargos. J. Control. Release 337, 646–660. doi:10.1016/j.jconrel.2021.08.013 • Huang, Y., Yu, Q., Chen, Z., Wu, W., Zhu, Q., and Lu, Y. (2021). In vitro and in vivo correlation for lipid-based formulations: current status and future perspectives. Acta Pharm. Sin. B 11, 2469–2487. doi:10.1016/j.apsb.2021.03.025 • Ameta, R. K., Soni, K., and Bhattarai, A. (2023). Recent advances in improving the • bioavailability of hydrophobic/lipophilic drugs and their delivery via self-emulsifying formulations. Colloids Interfaces 7, 16. [Online]. doi:10.3390/colloids7010016 • Nakmode, D., Bhavana, V., Thakor, P., Madan, J., Singh, P. K., Singh, S. B., et al. • (2022a). Fundamental aspects of lipid-based excipients in lipid-based product development. Pharmaceutics, 14 [Online]. • Yajima, T., Imai, K., & Awashima, M. (2018). Physicochemical properties of poorly water-soluble drugs. International Journal of Pharmaceutics, 547(1), 27-37. doi: 10.1016/j.ijpharm.2018.04.033: doi: 10.1016/j.ijpharm.2018.04.033
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.